v3.26.1
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenue:    
Total revenue $ 106,677 $ 93,881
Cost and operating expenses:    
Cost of revenue from sale of therapies (434) (831)
Research and development expense (61,113) (56,468)
Selling, general and administrative expense (37,850) (40,198)
Income (Loss) from operations 7,280 (3,616)
Other income (expense):    
Interest income 3,418 4,176
Interest expense (3,051) (3,025)
Foreign currency gains 3,849 3,080
Other income, net 1,776 5,469
Net income before income taxes 13,272 6,084
Income tax expense (301) (1,061)
Net income 12,971 5,023
Other comprehensive income (loss):    
Exchange differences on translation of foreign operations (7,289) 673
Total comprehensive income $ 5,682 $ 5,696
Basic net income per share (in USD per share) $ 0.26 $ 0.10
Basic weighted-average number of shares outstanding (in shares) 50,754,763 50,086,684
Diluted net income per share (in USD per share) $ 0.25 $ 0.10
Diluted weighted-average number of shares outstanding (in shares) 52,934,787 51,949,798
Revenue from sale of therapies, net    
Revenue:    
Total revenue $ 106,677 $ 93,881